Since DVT can lead to life-threatening complications like a pulmonary embolism (also known as a PE), patients on Ozempic, Wegovy, or any other injectable with known risk factors should be monitored closely for signs of thrombosis and advised on preventive measures like maintaining mobility and hydration
A separate product, semaglutide subcutaneous injection (Wegovy), is indicated as an adjunct to lifestyle modifications for weight loss and chronic weight management in obese (BMI 30 kg/m2 or greater) or overweight adults (BMI 27 kg/m2 or greater) with at least 1 weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Reference values for IGF-I serum concentrations: Comparison of six immunoassays
Injectable manufacturers and pharma remain bullish As pills gain a foothold in the colossal GLP-1 market, West Pharmaceutical Services announced in late March that it is revving up injectable therapy manufacturing capacity with a new 165,000 square foot facility